Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

Praxis Precision Medicines, Inc.PRAX · healthcare
GradeNonecomputable_factors_below_threshold: 6 of 14 inputs computable; 7 are required
Reliability0.91 AUCfailure model, filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate1.01% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size band$591M to $2.67B assetstotal assets $937.9M[1]
Standard universeoutsiderevenue above $1M and assets above $10M[1-2]
Warningsdilution, thin data, degenerate inputsnot computable: fortress balance sheet
Inputs computable6 of 14
Graded fromfilings received through Feb 19, 2026232 days before the rescan; every figure keyed to the SEC receipt date
Last close$263.402026-10-08; market equity $7.4B; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$200$400NovDecJanFebMarAprMayJunJulAugSepOct$263.55
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Mar 21, 2021nonen/aQ3
Feb 21, 2023nonen/aQ2
Mar 21, 2025nonen/aQ3
Feb 21, 2026nonen/aQ4

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Feb 19, 2026; the document on sec.gov.

We are a fully integrated, leading central nervous system, or CNS, precision neuroscience biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and both rare and more prevalent neurological disorders.

Warnings [top]

Dilution. split-adjusted year-over-year share growth is 38.1%[3-4]
Thin data. 6 of 14 grade factors are computable; minimum is 7
Degenerate inputs. latest revenue or assets are at or below the $100,000 validity floor[1-2]

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 51.9
Gross profitabilitynot computable32.2%
one or more required annual facts are missing
Return on invested capitalnot computable9.3%
one or more required annual facts are missing
Accruals ratio(7.6%)[1,5-7](6.6%)51.98112025-12-31
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 0
Solvency, sleeve percentile 15.1
Twelve-month failure probability0.04%0.07%23.12482026-06-30
Altman Z double-prime12.98[1,8-13](0.31)6.47562025-12-31
Net debt to EBITDAnot computable1.82x
one or more required annual facts are missing
Interest coveragenot computable(4.51x)
one or more required annual facts are missing
Current ratio10.22x[8-9]2.96x16.08392025-12-31
Growth and financing, sleeve percentile 37.2
Revenue growth, three-year compoundnot computable10.0%
four annual observations are required; found 3
Free cash flow growth, three-year compoundnot computable10.9%
current FCF must be positive and base FCF must exceed $100,000
Reinvestment ratenot computable37.1%
pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years101.2%[1,7,14-15]2.1%2.37042025-12-31
Net share issuance, one year38.1%[3-4]2.5%72.06342026-02-16

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month560.9%8.0%99hotter than 99 of 100 peers
Distance from 52-week high(31.8%)(31.4%)49closer to its high than 49 of 100 peers
EBIT to enterprise valuenot computable(1.5%)required accounting or market input is missing
Free cash flow yield(3.4%)(1.0%)44pricier than 56 of 100 peers
Book value to price0.180.2838pricier than 62 of 100 peers
Sales to price0.000.310pricier than 100 of 100 peers
Composite equity issuance, five years238.5%20.3%93more equity-funded than 93 of 100 peers
Relative strength against the sector, log excess return1.68(0.14)99ahead of 99 of 100 peers

Inputs: market equity $7.4B; EBIT -$326.2M; free cash flow -$249.1M; book equity $1.3B; sales $0; cash $474.8M[16].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zero(62.8%)✗ fail[5,7]
Operating cash flow above zero-$249.1M✗ fail[6]
Return on assets improved145.1 pts✓ pass[5,7,14,17]
Operating cash flow exceeds net income$54.2M✓ pass[5-6]
Long-term leverage felln/a[1,7,14]
Current ratio improved(54.8 pts)✗ fail[8-9,18-19]
No new shares issued38.1%✗ fail[3-4]
Gross margin improvedn/a
Asset turnover improved(9.7 pts)✗ fail[2,7,14,20]
Cash, filings, liquidity
Cash and equivalents$474.8M[21]
Operating cash flow, four quarters-$305.1M[6,21-25]
Months of runway18.7
Late filings, two years0
NT 10-K or NT 10-Q
Days since last periodic filing64
10-Q received Aug 6, 2026
Median daily dollar volume$118.6M
63 sessions
Days since newest grade input232

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$937.9M2025-12-312026-02-1910-Kfiling · viewer · series
2revenueus-gaap:Revenues$02025-12-312026-02-1910-Kfiling · viewer · series
3shares outstandingdei:EntityCommonStockSharesOutstanding27,850,8332026-02-162026-02-1910-Kfiling · viewer · series
4shares outstandingdei:EntityCommonStockSharesOutstanding20,163,2502025-02-262025-02-2810-Kfiling · viewer · series
5net incomeus-gaap:NetIncomeLoss-$303.3M2025-12-312026-02-1910-Kfiling · viewer · series
6operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$249.1M2025-12-312026-02-1910-Kfiling · viewer · series
7assetsus-gaap:Assets$483.1M2024-12-312026-02-1910-Kfiling · viewer · series
8current assetsus-gaap:AssetsCurrent$610.9M2025-12-312026-02-1910-Kfiling · viewer · series
9current liabilitiesus-gaap:LiabilitiesCurrent$59.8M2025-12-312026-02-1910-Kfiling · viewer · series
10retained earningsus-gaap:RetainedEarningsAccumulatedDeficit-$1.1B2025-12-312026-02-1910-Kfiling · viewer · series
11operating incomeus-gaap:OperatingIncomeLoss-$326.2M2025-12-312026-02-1910-Kfiling · viewer · series
12book equityus-gaap:StockholdersEquity$878.1M2025-12-312026-02-1910-Kfiling · viewer · series
13liabilitiesus-gaap:Liabilities$59.8M2025-12-312026-02-1910-Kfiling · viewer · series
14assetsus-gaap:Assets$87.9M2023-12-312025-02-2810-Kfiling · viewer · series
15assetsus-gaap:Assets$115.1M2022-12-312024-03-0510-Kfiling · viewer · series
16shares outstandingdei:EntityCommonStockSharesOutstanding27,919,9882026-07-312026-08-0610-Qfiling · viewer · series
17net incomeus-gaap:NetIncomeLoss-$182.8M2024-12-312026-02-1910-Kfiling · viewer · series
18current assetsus-gaap:AssetsCurrent$404.4M2024-12-312026-02-1910-Kfiling · viewer · series
19current liabilitiesus-gaap:LiabilitiesCurrent$37.5M2024-12-312026-02-1910-Kfiling · viewer · series
20revenueus-gaap:Revenues$8.6M2024-12-312026-02-1910-Kfiling · viewer · series
21cashus-gaap:CashAndCashEquivalentsAtCarryingValue$474.8M2026-06-302026-08-0610-Qfiling · viewer · series
22operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$163.7M2026-06-302026-08-0610-Qfiling · viewer · series
23operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$86.2M2026-03-312026-05-0710-Qfiling · viewer · series
24operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$172.7M2025-09-302025-11-0510-Qfiling · viewer · series
25operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$107.7M2025-06-302026-08-0610-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.